Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2014-02-17 Capital/Financing Update
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 3B 11 pages 88.4KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, issue price, purpose of the issue, and compliance with ASX rules. It references specific ASX rules (2.7, 3.10.3, etc.) and includes sections on quotation of securities and calculation of placement capacity under ASX rules. The document is a formal announcement related to the issuance and quotation of additional securities by Genetic Technologies Limited. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement.
2014-02-17 English
Patent re-examination certificate issued 1 page 106
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 12 February 2014 regarding the issuance of a Patent Re-Examination Certificate by the USPTO. It discusses the reaffirmation of patent claims and includes statements from the company's acting CEO. There are no financial statements, earnings data, or detailed management analysis. The document is a regulatory announcement about intellectual property status, not a financial report or meeting material. It is relatively short (3634 characters) and serves as a formal announcement to the market. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-02-11 English
Appendix 3B 11 pages 88.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, terms, issue price, purpose of the issue, and quotation application to the ASX (Australian Securities Exchange). It references specific ASX rules (Rule 2.7, 3.10.3, etc.) and includes sections about security holder approvals, quotation agreements, and placement capacity calculations under ASX rules 7.1 and 7.1A. The document is a formal announcement of a new share issue and application for quotation of additional securities, consistent with regulatory filings for capital raising activities. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is the announcement itself, not a brief notice or report publication announcement.
2014-02-11 English
Quarterly Reports - 31 December 2013 10 pages 54.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2013'. It contains detailed operational and financial information for the quarter, including cash receipts, revenues, capital raising, convertible notes, licensing activities, and corporate matters such as changes in CEO and board members. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year, along with the detailed quarterly operational update, clearly identifies this as an Interim / Quarterly Report. The document length (15,000 characters) and content confirm it is the report itself, not merely an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q2 2014
2014-01-29 English
Appendix 3B 11 pages 88.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, terms of the securities, purpose of the issue, and compliance with ASX rules. It references specific ASX rules (2.7, 3.10.3, etc.) and includes sections on quotation of securities and warranties to ASX. The document is a formal announcement related to the issuance and quotation of additional shares and convertible notes, which aligns with capital raising activities. It does not contain financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a report of voting results, management changes, or legal proceedings. The document is a regulatory announcement about new share issues and capital changes. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (15,000 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2014-01-19 English
GTG announces continued growth in number of BREVAGen tests 2 pages 134.1KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated 8 January 2014 from Genetic Technologies Limited reporting on the growth in the number of BREVAGen tests during the December quarter ended 31 December 2013. It provides specific quarterly operational data (number of test samples received) and discusses business growth trends. The document is relatively short (3974 characters) and focuses on operational performance metrics rather than comprehensive financial statements or detailed management analysis. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a regulatory filing or certification. It is an update on business activity and growth, typical of a Capital/Financing Update or operational performance announcement. Given the content and context, the most appropriate classification is Capital/Financing Update (CAP).
2014-01-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.